News
GKOS
245.72
-0.13%
-0.31
Glaukos (GKOS) Stock May Be 33% Undervalued As It Joins A New Index
Simply Wall St · 13h ago
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
NASDAQ · 1d ago
Glaukos (GKOS) Jumped, What Is Behind The Fresh Attention?
Simply Wall St · 4d ago
Weekly Report: what happened at GKOS last week (1102-1106)?
Weekly Report · 4d ago
Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet
Benzinga · 5d ago
Learn Why The Bull Case For Glaukos Stock Could Change Following S&P 400 Inclusion
Simply Wall St · 6d ago
Glaukos Corporation Outlines Product Roadmap and Commercial Updates in November 2026 Investor Presentation
NASDAQ · 11/06 16:31
Glaukos Highlights Procedural and Sustained-Release Eye Therapies
TipRanks · 11/06 12:30
Why Glaukos Doubters Were Wrong Before A 169% Gain
Simply Wall St · 11/06 09:34
Glaukos (GKOS) Stock Could Still Look Reasonable Despite Its 348% Run
Simply Wall St · 11/04 07:35
Notable ETF Inflow Detected - IJR, PAYC, GKOS, MTCH
NASDAQ · 11/03 15:52
Glaukos Announces Participation in Upcoming Investor Conferences
Barchart · 11/03 06:00
Glaukos Earnings Call Signals Strong Growth Ahead
TipRanks · 11/03 00:14
Glaukos (GKOS) Just Moved, What Is Drawing Fresh Attention?
Simply Wall St · 11/02 14:14
Okta Stock Can Find More Buyers as It Joins the S&P 500
Barron‘s · 11/02 11:21
Weekly Report: what happened at GKOS last week (1026-1030)?
Weekly Report · 11/02 09:57
Glaukos Consensus Price Target Raised 22.10% to $247.31
NASDAQ · 11/02 07:45
Earnings Beat Might Change The Case For Investing In Glaukos Stock (GKOS)
Simply Wall St · 10/31 09:36
Okta To Replace Kenvue In S&P 500
NASDAQ · 10/31 01:30
Okta Is Joining the S&P 500 as Kenvue Leaves
Barron‘s · 10/30 22:20
More
Webull provides a variety of real-time GKOS stock news. You can receive the latest news about Glaukos Corp through multiple platforms. This information may help you make smarter investment decisions.
About GKOS
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.